The state of Florida currently has 7 active clinical trials seeking participants for Narcolepsy research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
Recruiting
The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime sleepiness (EDS) as assessed by the Maintenance of Wakefulness Test (MWT) in adult participants with narcolepsy type 1 (NT1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: PharmaDev Clinical Research, Miami, Florida
Conditions: Narcolepsy Type 1 (NT1)
Observational Study of LUMRYZ in Narcolepsy
Recruiting
This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Jeremy D McConnell, MD PA, Bradenton, Florida
Conditions: Narcolepsy
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Recruiting
The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/16/2024
Locations: Alkermes Investigator Site, Brandon, Florida +2 locations
Conditions: Narcolepsy Type 1
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/16/2024
Locations: Alkermes Investigator Site, Brandon, Florida +2 locations
Conditions: Narcolepsy Type 2
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
Recruiting
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy... Read More
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
12/10/2024
Locations: Takeda Site 4, Orlando, Florida
Conditions: Narcolepsy Type 1
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Recruiting
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
09/24/2024
Locations: Florida Pediatric Research Institute, Orlando, Florida
Conditions: Narcolepsy Type 1
Child and Adolescent Registry for Participants With Narcolepsy
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/13/2024
Locations: University of South Florida, Tampa, Florida
Conditions: Narcolepsy